Organisation paid for research Program year 2024 Source: CMS Open Payments

Illinois Gastroenterology Group

Neither a doctor nor a teaching hospital

Research payments

$49,994

83 payments

Through program year 2024, Illinois Gastroenterology Group is reported as receiving $49,994 in research payments, across 83 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$380	13
2023	Research	$1,365	36
2022	Research	$644	22
2021	Research	$236	1
2020	Research	$6,600	3
2019	Research	$40,769	8

Breakdown

Who paid Research payments · program years 2019–2024

Takeda Pharmaceuticals U.S.A., Inc. $37,569 7 payments
UCB Biosciences Inc. $9,600 3 payments
Arena Pharmaceuticals, Inc. $2,389 71 payments
E.R. Squibb & Sons, L.L.C. $236 1 payment
Pfizer Inc. $200 1 payment

Studies the money was for Research payments · program years 2019–2024

ENTYVIO Outcomes in Real-World Bio-naive Ulcerative Colitis and Crohns Disease Patients EVOLVE $26,100 4 payments
EntyvioVedolizumab Long Term Study $11,469 3 payments
A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's Disease $6,400 2 payments
A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease $3,200 1 payment
An Openlabel Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $2,389 71 payments
Phase 2 UC Primary represents Induction $236 1 payment
Observational Real World Study of Inflectra in Patients With Inflammatory Bowel Disease Ibd in the United States and Canada $200 1 payment

What the money was spent on Research payments · program years 2019–2024

Other $37,569 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.